HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026 …
Post
-
-
Malaria vector Anopheles (Nyssorhynchus) darlingi evolving insecticide resistance
Malaria is a bloodborne parasitic disease wherein Plasmodium parasites are transmitted by mosquito vectors. Despite efforts to control mosquito populations, …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
-
Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after …
-
Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 …
-
Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after …
-
Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 …
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in adult …
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming …
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results …
-
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
A partnership between Europe and Africa has seen the initiation of a clinical trial of an anti-malaria drug in early …
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial …
-
AI-driven cardiometabolic clinical trial recruitment and retention
For sponsors running cardiometabolic programs, early clinical development often hinges on one question: can a site deliver predictable recruitment, high …
-
Epitopea receives MHRA and REC approvals for OVACT ovarian cancer trial
Epitopea has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) in …
-
CatalYm doses first patient in Phase II/III VINCIT trial
CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its …
